Faben A Cruz

Title: Faben A Cruz: Innovator in Pharmaceutical Chemistry

Introduction

Faben A Cruz is a notable inventor based in Burlingame, CA (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds aimed at treating various metabolic and cognitive disorders.

Latest Patents

Faben A Cruz holds a patent for the "Preparation of tetrahydroindazole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors." This patent includes compounds of formula I and their pharmaceutically acceptable salts, esters, and prodrugs. These compounds serve as DGAT2 inhibitors and are designed to treat conditions such as hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, and cardiorenal diseases like chronic kidney diseases and heart failure. The patent also outlines methods for synthesizing these compounds and their pharmaceutical compositions.

Career Highlights

Faben A Cruz is currently employed at Merck Sharp & Dohme LLC, where he continues to advance his research in pharmaceutical innovations. His work has led to the development of important therapeutic agents that address significant health issues.

Collaborations

Faben collaborates with esteemed colleagues such as Chen Cheng and Yeon-Hee Lim, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Faben A Cruz exemplifies the spirit of innovation in the pharmaceutical industry through his groundbreaking work on DGAT2 inhibitors. His contributions are poised to make a lasting impact on the treatment of various diseases and conditions.